| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 9.24 | 45.5% | 19.6% |
| Total Income | 9.24 | 45.5% | 19.6% |
| Expenditure | 35.31 | 42.9% | 29.7% |
| PBT | — | ||
| Net Profit | 16.90 | 136.2% | 144.2% |
| OPM | — | ||
| NPM | 100.00% | ||
| EPS | 0.05 | 125.0% | 129.4% |
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib
28 Jul 2026 · 28 Jul, 1:36 am
Summary
Gossamer Bio announced significant updates including a planned NDA submission for seralutinib in PAH in September 2026, following a positive FDA meeting. The company has also reacquired worldwide rights to seralutinib from Chiesi, consolidating global control and securing the majority of the program's long-term economics. Stockholder approval for a convertible note exchange and a reverse stock split were also secured, aimed at strengthening the capital structure. Preliminary cash, cash equivalents, and marketable securities were approximately $57 million as of June 30, 2026.
Key Highlights
- 1
Gossamer Bio is proceeding toward a planned NDA submission for seralutinib for the treatment of patients with PAH in September 2026, following a productive Pre-NDA Type B meeting with the FDA.
- 2
The Company has reacquired worldwide development and commercial rights to seralutinib from Chiesi, consolidating global control of the program.
- 3
Gossamer's stockholders approved proposals related to the convertible note exchange and authorized the Company to effect a reverse stock split, supporting a strengthened capital structure.
- 4
On a preliminary basis, cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30, 2026.
- 5
The termination agreement requires Chiesi to make a one-time $5 million payment to Gossamer shortly after signing, settling all outstanding and future obligations under the prior collaboration.
- 6
Gossamer expects to effect the reverse stock split in or promptly following the third quarter of 2026.
Management Comments
Faheem Hasnain
This is a defining moment for Gossamer. Following a very productive and collaborative engagement with FDA at our Pre-NDA Type B meeting and now with the FDA's final meeting minutes in hand, we are moving forward with a planned NDA submission for seralutinib in PAH in September. After years of disciplined execution, we are now closer than ever to bringing forward what we believe can be a first-in-class, important new medicine for PAH patients who need better options. Reacquiring the worldwide rights to seralutinib is equally significant. It returns global development and commercialization decisions to Gossamer and secures the substantial majority of the program's long-term economics for our shareholders, positioning us to realize the full strategic and financial value of seralutinib across PAH and future indications. We enter the second half of 2026 with increased clarity on our planned regulatory path, worldwide rights in hand, a healthier balance sheet and real momentum behind us. There has never been a more exciting time in Gossamer's history, and we look forward to the milestones ahead.
Informational and educational content only. Not investment advice.